Korsuva

Chemical Namedifelikefalin
Dosage FormInjection (intravenous; 50 mcg/mL)
Drug ClassReceptor agonists
SystemUrinary
CompanyCara Therapeutics
Approval Year2021

Indication

  • For the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Korsuva (difelikefalin) Prescribing Information2021Vifor (International) Inc., St. Gallen, Switzerland
Document TitleYearSource
A Phase 3 trial of difelikefalin in hemodialysis patients with pruritus.2019The New England Journal of Medicine